Welcome to our dedicated page for QT Imaging Holdings news (Ticker: qti), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
QT Imaging Holdings (QTI) provides cutting-edge diagnostic imaging solutions for healthcare and industrial applications. This page serves as a comprehensive resource for official company announcements, financial updates, and technology developments.
Access timely updates on product innovations, regulatory milestones, and strategic partnerships. Investors and industry professionals will find curated press releases covering earnings reports, research breakthroughs, and operational expansions.
All content is verified for accuracy and relevance, offering a centralized hub for tracking QTI's advancements in medical imaging technology. Key focus areas include high-resolution systems, quality control processes, and cross-industry applications of imaging solutions.
Bookmark this page for direct access to primary source materials about QTI's market position and technological leadership. Check regularly for updates reflecting the company's commitment to imaging innovation and operational excellence.
QT Imaging Holdings (NASDAQ:QTI) has announced the release of a new machine learning-enabled image interpolation algorithm that reduces scan times by approximately 50%. The technology allows the system to skip alternate scan levels while maintaining high image quality and diagnostic accuracy.
The advancement aims to enhance patient comfort through shorter scanning times and improve operational efficiency by increasing patient throughput. The company will present this development at the SPIE Medical Imaging 2025 conference in San Diego.
QTI continues to expand its clinical and R&D efforts through collaborations with institutions including the National Institutes of Health, Sunnybrook Health Sciences Centre, and the Stephenson Cancer Center at the University of Oklahoma, focusing on advancing cancer detection and treatment precision.
QT Imaging Holdings (NASDAQ:QTI), a medical device company, announces the elimination of its short-term liabilities and forecasts robust revenue growth for 2025 and 2026. The company has amended its convertible promissory notes with YA II PN, and Funicular Funds, LP, extending the maturity date to March 31, 2026, with no payments due until then. QT Imaging projects revenue of $18M in 2025 and $27M in 2026, a significant increase from 2024. The company aims to deliver a minimum of 40 scanners in 2025 and 60 scanners in 2026, totaling $45M in revenue over the two years. Further details are available in the SEC Form 8-K filed on January 10, 2025.
QT Imaging Holdings (NASDAQ:QTI) has announced the expansion of its Breast Acoustic CT Scanner to Couri Center for Gynecology and Integrative Women's Health in Peoria, IL. The shipment was executed in partnership with NXC Imaging, Inc. The technology offers enhanced breast imaging capabilities, particularly beneficial for patients with dense breasts and those at elevated risk of breast cancer. The system provides painless, true 3D imaging with high resolution. QTI will present its technology at the Empowered Wellness: A Women's Health Summit on March 8, 2025, sponsored by the Couri Center.
QT Imaging Holdings (NASDAQ:QTI) announces its participation in the Radiological Society of North America 2024 Annual Meeting in Chicago, December 1-5, 2024. Dr. Bilal Malik, Chief Science Officer, will present on December 4th at 9:30 am, focusing on Breast Ultrasound Techniques. His presentation will compare quantitative transmission ultrasound imaging with digital breast tomosynthesis (DBT), showcasing results from a multi-reader, multi-case observer study.
The study demonstrates QTI's technology performs comparably to DBT, potentially offering a safe and more accessible option for breast cancer screening and diagnosis.
QT Imaging Holdings (NASDAQ: QTI) reported Q3 2024 financial results with commercial revenue of $1.0 million, including $0.9 million from scanner sales. The company achieved a gross margin of 63%, up from 51% in Q2 2024. Net loss was $3.6 million, including $1.5 million in convertible note interest expenses. The company completed an engineering and clinical feasibility study with its strategic partner and secured a $2.56 million PIPE investment from board members. QTI also amended its convertible note with YA II PN, reducing the principal balance to $8.6 million and extending maturity to March 2026.
QT Imaging Holdings (NASDAQ:QTI) has secured a $1M PIPE investment from company insiders, led by Board Chairman Dr. Avi Katz and CEO Dr. Raluca Dinu, along with four other board members. The deal includes the purchase of 4,383,558 unregistered shares at $0.584 per share with matching warrants at $0.672. Additionally, GigAcquisitions5, agreed to cancel a $1.56M promissory note. The share price represents a 10% premium over the 5-day VWAP. The financing, expected to close by November 29, 2024, will provide working capital as bridge funding while pursuing strategic partnerships and commercialization plans.
QT Imaging Holdings (NASDAQ:QTI) has received a third-year renewal of its five-year NIH/NCI research grant. The study, conducted in collaboration with Sunnybrook Health Sciences Centre and The University of Illinois, aims to develop an accurate breast imaging approach for early identification of breast cancer patients' response to neoadjuvant chemotherapy (NAC). The QTI Breast Acoustic CT™ System has been successfully used to collect high-resolution breast images with biomarkers sensitive to cancer. The next phase will incorporate AI/ML techniques to improve NAC efficacy estimates based on quantitative biomarkers from QTI scans and backscatter analysis.
QT Imaging Holdings (NASDAQ:QTI) has announced a favorable amendment to its $10,000,000 convertible promissory note with YA II PN, The amendment, executed on September 26, 2024, follows a trigger event on September 11, 2024, that led to a $1,500,000 payment by the company on September 13, 2024. Key changes include:
- Extension of the note's maturity date by approximately 6 months to December 15, 2025
- Deferral of all monthly cash payments until January 15, 2025
- Reduction of monthly payment obligations from $1,500,000 to $600,000 during trigger events
- Waiver of potential Nasdaq delisting as an event of default
CEO Dr. Raluca Dinu expressed gratitude for the partnership, stating that the amendment provides runway for QTI's first-year plan as a public company, focusing on commercial shipments of Breast Acoustic CT™ Scanners in the United States.
QT Imaging Holdings (NASDAQ:QTI), a medical device company specializing in innovative body imaging systems, has announced its participation in the IEEE International Ultrasonics Symposium (IUS) in Taipei, Taiwan, from September 22-26, 2024. Dr. James Wiskin will represent QTI in the Medical Imaging subsection, presenting on a novel application of machine learning for image 'cleaning' or artifact removal. This technique preserves diagnostic and quantitative information for accurate diagnoses, applicable to breast images as well as high-resolution orthopedic and pediatric 3D images produced by QTI's technology.
QT Imaging Holdings (NASDAQ:QTI) announces the expansion of its Breast Acoustic CT™ Scanner to Vitality Renewal Functional Medicine in Crystal Lake, Illinois. Dr. Yvonne Karney, the founder, expresses excitement about offering this FDA-cleared, non-invasive 3D breast imaging technology in the Chicagoland area. The QTscan™ provides detailed images without compression or radiation and is more accurate than mammography and hand-held ultrasound for certain breast structures. Dr. Karney highlights the limitations of mammography, especially for women with dense breasts, and emphasizes the importance of offering women alternative screening options. QTI's CEO, Dr. Raluca Dinu, reaffirms the company's commitment to expanding access to their breast imaging technology nationwide.
